San Diego, CA — Evofem Biosciences Inc. (OTCID: EVFM), a women-led biotech innovator in sexual and reproductive health, proudly announced today that CEO Saundra Pelletier has received the prestigious Trailblazing Female Founders Award at the 2025 STIMULATE Conference. The award ceremony, hosted in Nashville, Tennessee, celebrates visionary women shaping the future of sexual wellness and healthcare.
Leading with Purpose in Sexual and Reproductive Health
Held annually, the STIMULATE Conference is the only U.S. trade show exclusively dedicated to sexual wellness, women’s health innovation, and empowerment. This year’s theme resonates powerfully with Pelletier’s lifelong mission to destigmatize reproductive conversations and advocate for medically accurate, empowering language in healthcare.
The recognition aligns with Evofem’s ongoing Say Vagina Month campaign—an initiative designed to break taboos and address the censorship surrounding vaginal health.
“Let’s talk about sex, not just prevention,” said Pelletier. “This award isn’t just about business success—it’s about reclaiming the conversation for women everywhere. Women deserve honesty, pleasure, and agency in how we talk about our bodies and our choices.”
Groundbreaking Work with PHEXXI® and SOLOSEC®
Evofem’s groundbreaking product PHEXXI®—a hormone-free, on-demand vaginal contraceptive gel—continues to make waves in the birth control market. Clinical data published in the Journal of Sexual Medicine shows that nearly 90% of women using PHEXXI in the Phase 3 AMPOWER trial experienced improved or sustained levels of sexual satisfaction.
In addition, SOLOSEC®, Evofem’s FDA-approved oral antibiotic for bacterial vaginosis (BV) and trichomoniasis, offers a complete course of treatment in a single dose—providing convenience and clinical efficiency for women’s health providers.
Both products are being promoted to U.S. OB/GYNs and will soon enter global markets, with launches expected in the UAE by 2026 through new strategic partnerships.
Advancing the Women’s Health Agenda
Under Pelletier’s leadership, Evofem remains a leader in women’s sexual health innovation, with a core mission to create science-backed, access-oriented, and empowerment-driven solutions. The company’s work goes beyond product sales—it engages in bold public health advocacy that redefines how birth control and vaginal health are understood in both medical and social contexts.
The award from STIMULATE places Pelletier alongside a group of pioneering women who are reshaping health narratives and markets historically neglected or misunderstood.
Acquisition by Aditxt and the Road Ahead
In a strategic move to strengthen its reach and innovation pipeline, Evofem is currently working toward a planned acquisition by Aditxt, Inc. (Nasdaq: ADTX), under a definitive merger agreement. The deal, if closed successfully, will embed Evofem’s women’s health program into Aditxt’s social innovation platform, potentially accelerating access to sexual and reproductive health solutions worldwide.
However, the completion of the merger remains contingent on regulatory approvals and financing, including a required $17 million in funding for Evofem’s senior secured obligations.
About Evofem Biosciences
Evofem is a trailblazer in hormone-free contraceptives and female-focused antibiotics. With a commercial team focused on OB/GYN engagement and a vision to expand internationally, Evofem continues to bridge science and advocacy in women’s reproductive health.
